FDA accepts Bayer's Biologics License Application for new investigational recombinant FVIII therapy to treat hemophilia A in children and adults.
Progress made by Baxter during clinical trial assessing the safety and optimal dosing level of BAX 335, an investigational factor IX (FIX) gene therapy.
New recombinant factor VIIa therapy expected to extend half-life for people with hemophilia A or B with inhibitors.
New Biogen Idec global partnership to use lentiviral vectors in developing gene therapies for hemophilia A and B.
Consider enrolling in clinical trial of HCV drugs designed for people with hemophilia.
Grifols announces larger vial size for ALPHANATE, its factor VIII/von Willebrand factor product.
RIXUBIS (Coagulation Factor IX [Recombinant]), manufactured by Baxter International, Inc., previously approved for adults, is now FDA-approved for children with hemophilia B.
A team of researchers is using genetically engineered tobacco plants to deliver factor VIII, without causing inhibitors or anaphylaxis, a life-threatening allergic reaction.
Achillion’s ACH-3102, a new therapy for patients with hepatitis C virus (HCV), performs well in 8-week clinical trial.
Expression and ABL collaborate to provide recombinant factor VIII product that is affordable and available to people with hemophilia in the developing world.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car